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SUMMARY
Intestinal adaptation is an important compensatory
response to the loss of intestinal length. The process is
complex, but a more thorough understanding will pave the
way for innovative therapies intended to amplify this
important response.
After massive small-bowel resection, the remnant bowel
compensates by a process termed adaptation. Adaptation
is characterized by villus elongation and crypt deepening,
which increases the capacity for absorption and digestion
per unit length. The mechanisms/mediators of this
important response are multiple. The purpose of this re-
view is to highlight the major basic contributions in
elucidating a more comprehensive understanding of this
process. (Cell Mol Gastroenterol Hepatol 2016;2:429–438;
http://dx.doi.org/10.1016/j.jcmgh.2016.05.001)
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Intestinal adaptation is an important response tomassive small-bowel resection (SBR) and represents a
mitogenic signal to the intestine culminating in a compen-
satory expansion in mucosal digestive and absorptive sur-
face area per unit length. Clinically, adaptation is heralded by
the gradual tolerance of enteral nutrition that could not be
tolerated at earlier time points. A complete adaptation
response allows for tolerance of all nutrition to be absorbed
from the gut, without the need for supplemental parenteral
feeding. The expression of several immediate–early genes
within the remnant bowel has been recorded to be increased
within hours of intestinal resection.1,2 Similarly, in a murine
model of SBR, alterations in wet weight as well as DNA and
protein content in the remnant bowel are increased as soon
as 24 hours, but before the initiation of enteral feeding.3
Adaptation is characterized structurally by taller villi and
deeper crypts, as well as enhanced rates of enterocyte pro-
liferation and apoptosis. Although these features are a
renowned characteristic of adaptation in animal models of
massive SBR, similar structural alterations have not been
described consistently in human beings. In one study, the
intestine was evaluated in a uniform population of infants
with neonatal necrotizing enterocolitis who required bowel
resection.4 Comparing villus height and crypt depth at the
normal margin of tissue at the time of resection with the time
of ostomy takedown showed signiﬁcant increases in both
parameters. In another report, a 70%–75% increase in villus
height was documented in the small intestines of 13 patients
at 2 years after jejuno-ileal bypass.5 In addition, signiﬁcant
increases in crypt depth and cell number/crypt in the colons
of 12 patients with jejunocolonic anastomosis compared with
healthy controls was identiﬁed at a mean of 9.8 years after
resection.6 Unfortunately, the histologic status of the small
intestine was not evaluated in that study. In contrast, other
studies have failed to show changes in rates of enterocyte
proliferation, crypt depth, or villus height in the small intes-
tine of patients with short-gut syndrome compared with
controls.7–9 All of the earlier-mentioned human studies
comprised small numbers of patients, variable lengths of
resected intestine, assorted amounts of enteral feeding, and
analysis at single time points after SBR. Despite these limi-
tations, animal models for studying resection-induced adap-
tation continue to provide important mechanistic insights.
Mechanisms of Adaptation
The mechanisms and mediators of intestinal adaptation
are multifactorial and include intraluminal nutrients,
gastrointestinal secretions, as well as hormones10,11
(Figure 1). In general, most research has focused on
various growth factors and how they affect rates of
enterocyte proliferation as the primary driver of resection-
induced mucosal growth. It should be considered, howev-
er, that enhanced rates of enterocyte proliferation actually
may occur secondary to growth of subepithelial structures.
Intraluminal Nutrients
Enteral nutrients appear to stimulate intestinal adapta-
tion via several mechanisms including direct contact with
epithelial cells as well as stimulated secretion of trophic
gastrointestinal hormones and pancreaticobiliary secre-
tions.12 The contributions of luminal nutrients to the
adaptive response of the intestine is underscored by the
Abbreviations used in this paper: EGF, epidermal growth factor; GH,
growth hormone; GLP-2, glucagon-like peptide-2; IGF-1, insulin-like
growth factor-1; LA, lactate-accumulator; PN, parenteral nutrition; Rb,
retinoblastoma protein; SBBO, small-bowel bacterial overgrowth;
SBR, small-bowel resection.
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observations that gut mucosal atrophy is associated with
starvation and is reversed by refeeding. Furthermore, sur-
gical transposition of a segment of the ileum into the more
proximal intestinal stream results in structural and func-
tional “jejunalization” of the transposed ileum.13,14 Not only
is the presence of luminal nutrition important for adapta-
tion, but so is the nutritional composition. Luminal admin-
istration of non-nutrient substrates has little effect on
adaptation. More complex nutrients requiring more meta-
bolic energy to absorb and digest have been suggested to
induce the greatest adaptation response, presumably by
virtue of an increased functional workload of the enterocyte.
Enteral fats appear to be the most trophic of the macronu-
trients in inducing adaptation.15 More speciﬁcally, longer-
chain and more polyunsaturated fats as present in ﬁsh oil
may provide an even greater adaptive stimulus.16–18
Gastrointestinal Secretions
Multiple experimental observations have contributed to
the notion that endogenous gastrointestinal secretions are
important for adaptation. Experimental models in which the
ampulla of Vater is transposed surgically to areas more
distal in the gastrointestinal tract induces villus hyperplasia
beyond the transposed segment.19,20 Bile alone has been
shown to stimulate intestinal RNA and DNA content when
delivered directly to the mid–small bowel, but the effect
seems to be more profound when combined with pancreatic
secretions.20 In other studies, pancreatic secretions seem to
be more trophic to the intestinal mucosa when compared
with bile.20 Further evidence that pancreaticobiliary secre-
tions are important for postresection adaptation is the
observation that somatostatin, an agent that dramatically
diminishes the output of endogenous gastrointestinal
Figure 1. Factors that
play a role in resection-
induced intestinal adap-
tation.
430 Brad W. Warner Cellular and Molecular Gastroenterology and Hepatology Vol. 2, No. 4
secretions, also is associated with an inhibited adaptation
response.21
Humoral Factors
A surgical model of vascular parabiosis in which 2 rats
share a common circulation has provided one of the most
compelling studies endorsing the contributions of hormones
to resection-induced adaptation.22 In that report, intestinal
resection in one animal was associated with adaptive
changes in the intestine of the other unoperated animal.
Multiple endogenous humoral factors that have been sug-
gested to play a role in intestinal adaptation including
growth hormone, insulin-like growth factor, glucagon-like
peptide-2, epidermal growth factor (EGF), leptin,
thyroxine, and corticosteroids, to name but a few.23 Many of
these factors either have been found to be increased in the
serum of patients who have undergone SBR, or exogenous
administration of these agents after SBR has resulted in
enhanced parameters of adaptation.
Growth Hormone
Growth hormone (GH) is a 191–amino acid, single-chain
protein produced in the anterior pituitary gland. This
growth factor is known to be a major regulator of postnatal
growth in mammals as well as play an important role in the
regulation of lipid and carbohydrate metabolism.24,25
Because GH has been shown to induce growth and prolif-
eration in many different tissues and cell lines, its role in the
setting of short-gut syndrome has been studied extensively.
The receptor for GH has been found throughout the intes-
tine: in cells of the muscularis propria, submucosa, muscu-
laris mucosa, lamina propria, and intestinal epithelium.26
Because of the widespread distribution for this receptor in
the gut, GH has been proposed to stimulate intestinal
growth directly. In addition to stimulating growth of the
intestinal layers directly, GH is a major stimulus for the
production of insulin-like growth factor-1 (IGF-1), another
intestinotrophic hormone, whose role in intestinal adapta-
tion will be discussed in later.
In animal studies, exogenous GH has resulted in signiﬁ-
cantly increased small-bowel length, mucosal height, jejunal
villus height, and/or glutamine and leucine transport in
animals that had undergone intestinal resection.27–29 In
contrast, other reports have failed to show an effect of GH
on postresection mucosal growth.30,31 GH appears to be
more effective in combination with glutamine, an
enterocyte-preferred fuel. Several, but not all, animal studies
evaluating GH plus glutamine have shown improvements in
structural measures of intestinal adaptation.32–35
In a clinical trial, Byrne et al36 showed clinical beneﬁt by
administering GH and glutamine in 10 patients with short-
bowel syndrome who had been on long-term parenteral
nutrition. This study inspired multiple subsequent clinical
trials with mixed results. In a 2010 Cochrane Review, Wales
et al37 analyzed 5 clinical trials of GH with or without
glutamine and suggested a positive effect of GH on weight
gain and energy absorption. In the majority of trials, the
effects were short-lived and returned to baseline shortly
after cessation of therapy. The evidence to recommend this
therapy therefore was inconclusive and the clinical utility of
this treatment was questioned. Somatropin is a recombinant
form of human GH and recently has been shown to enhance
fat-free mass through the stimulation of protein synthesis
and to decrease proteolysis in response to feeding.38 In that
study, improvements in de novo synthesis and intestinal
absorption increased glutamine availability over the physi-
ologic range, suggesting that beneﬁcial effects of GH may not
require supplemental glutamine.
IGF-1
IGF-1 is a hormone produced chieﬂy in the liver and to a
lesser degree in the gastrointestinal tract and has com-
manded much attention as an enterotrophic hormone.
Similar to GH, IGF-1 has been shown to enhance the rates of
enterocyte proliferation after SBR.39 These observations,
along with the localization of IGF-1 production, its receptor,
and regulatory binding proteins in the intestine, make IGF-1
an attractive target for modulating adaptation
responses.40,41
It has been considered that IGF-1 is the mediator of the
effects attributed to GH.32,42 Both functional and structural
parameters of adaptation have been shown to be ampliﬁed
by IGF-1. Vanderhoof et al43 found an increase in the activity
of the ileal digestive enzymes sucrase, maltase, and leucine
aminopeptidase when IGF-1 was given after SBR. In rats
with short-bowel syndrome, IGF-1 treatment allowed the
rats to be weaned from parenteral nutrition. In that study,
IGF-1–treated short-bowel rats also were found to have
greater body weights and increased lean body mass.
In addition to the effects of IGF-1 on enterocytes, our
laboratory has shown a possible effect of IGF-1 on the
smooth muscle of the intestine. We performed SBR pro-
cedures on transgenic mice who overexpressed IGF-1 spe-
ciﬁcally in smooth muscle cells.44 We found that these mice
increased the length of their remnant intestine far more
(approximately 2-fold) than nontransgenic control mice that
also underwent SBR. Of note, these transgenic mice did not
show the normal adaptive response of increasing villus
height and crypt depth in the early phases of adaptation.
The intestinal lengthening response preceded villus growth,
which was noted at later postoperative time points. These
experiments suggest that the IGF-1–stimulated muscular
lengthening might be an important trigger for enhanced
villus and crypt growth. As such, it is plausible to consider
that enterocyte proliferation occurs secondary to growth of
the underlying mesenchyme, as opposed to being the pri-
mary stimulus for villus lengthening.
In contrast with the positive ﬁndings described earlier,
adaptation responses appear to be preserved after SBR in
both IGF-1-null mice as well as in a strain of mice in whom
IGF-1–receptor expression was disrupted speciﬁcally in
enterocytes.45 These ﬁndings have several implications.
First, they suggest that enterocytes are not a major cell
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compartment for IGF-1–receptor signaling during adapta-
tion. Thus, the beneﬁcial effects of exogenous IGF-1 may
involve IGF-1 receptors in other cells within the bowel wall.
This notion would be supported by the magniﬁed intestinal
lengthening shown after SBR in mesenchymal IGF-1 trans-
genic mice as described earlier.44 In addition, these ﬁndings
would offer the possibility that other ligands (such as in-
sulin or IGF-2) for the IGF receptor may be able to
compensate for the lack of IGF-1 expression. Despite the
signiﬁcant preclinical work that has been performed, no
human clinical trials with IGF-1 have been reported.
Glucagon-Like Peptide-2
Glucagon-like peptide-2 (GLP-2) is an enterotrophic
hormone and a member of the pituitary adenylate cyclase
activating peptide glucagon superfamily. GLP-2 is synthe-
sized in enteroendocrine L cells of the distal ileum and
proximal colon.46,47 Within this 33–amino acid protein, the
second amino acid in the sequence is alanine, which makes
the hormone sensitive to degradation by the exopeptidase
dipeptidyl peptidase-4.48,49 Substitution of glycine for
alanine at position 2 makes a synthetic analog of GLP-2
(teduglutide) that is resistant to enzymatic degradation
and signiﬁcantly extends its half-life.50
GLP 2 exerts its effects through the GLP-2 receptor, which
has been identiﬁed on intestinal enteroendocrine cells,
enteric neurons, and subepithelial myoﬁbroblasts.51–53
Secretion of GLP-2 by intestinal L cells is driven by both
direct stimulation of nutrients in the distal bowel and vagally
mediated pathways, which are activated by the presence of
nutrients in the proximal bowel.54 Ingestion of nutrients,
particularly long-chain fatty acids, plays a major role in GLP-
2 secretion.55 In patients with short-bowel syndrome, the
presence of a colon in continuity with the small intestine is
important for nutrient-stimulated increases in GLP-2.56,57
This ﬁnding may help explain why the presence of the co-
lon reduces the likelihood that a patient with short-bowel
syndrome will require parenteral nutrition.
The intestinal effects of GLP-2 have been studied both in
animal models and in human clinical trials. When given to
rodents, GLP-2 stimulates intestinal mucosal growth.58,59 In
addition to elongated intestinal villi and crypts, GLP-2
administration augments rates of crypt cell proliferation
and attenuates rates of apoptosis. Other effects mediated by
GLP-2 include reduced gastric motility, inhibited gastric acid
secretion, and increased mesenteric blood ﬂow.60–62 GLP-2
also acts on the enteric nervous system, which may play a
key role in its ability to stimulate mucosal growth. After
administration of GLP-2, cellular changes have been detec-
ted in enteric neurons before affecting the intestinal crypts,
suggesting that many of the effects of GLP-2 may be medi-
ated by the enteric nervous system.52 Along this line, a
potential role for the enteric nervous system was suggested
by studies of Ret-heterozygous mutant mice who show
enhanced adaptation responses to SBR.63
In several studies, adult patients with short-bowel syn-
drome treated with teduglutide showed increases in villus
height and decreases in parenteral nutrition and ﬂuid
requirements.64–66 Teduglutide is now approved for clinical
use in parenteral nutrition–dependent adults with short-
bowel syndrome.67
Epidermal Growth Factor
Human EGF is a 53–amino acid protein found in plate-
lets, macrophages, urine, saliva, breast milk, and plasma.
EGF is a member of a family of ligands sharing a common
EGF receptor, which also includes transforming growth
factor, heparin-binding EGF-like growth factor, amphir-
egulin, epiregulin, epigen, betacellulin, and neuregulins
1–4.68 This growth factor has been shown to induce growth
in the epithelia of multiple tissues to include skin, lung,
tracheal, corneal, and gastrointestinal tract.69
An important role for EGF as a mediator of adaptation
initially was suggested by a study in which EGF was
administered to rats after SBR and showed signiﬁcant in-
creases in weight gain as well as other parameters of
adaptation.70 Through several subsequent experimental
paradigms, enhanced resection-induced adaptation re-
sponses have been veriﬁed after stimulation of the EGF
receptor either by exogenous EGF,71,72 in EGF transgenic
mice,73 or administration of another EGF-receptor ligand
(transforming growth factor-a).74 Alternatively, inhibiting
EGF-receptor signaling by removing the submandibular
glands, a major source of endogenous EGF in the mouse,75
performing SBR procedures in waved-2 mice with dimin-
ished EGF-receptor activity,76 or administration of a phar-
macologic EGF-receptor inhibitor77 all resulted in
attenuated adaptation responses.
Because the intestinal mucosa is a very dynamic organ
containing some of the most rapidly proliferating cells in the
body, the relationship between rates of cell production and
cell death must be precise. Any imbalance may result in
either intestinal mucosal atrophy or neoplasia. In studies
focused on mechanisms for EGF-receptor regulation of
proliferation showed that expression of the cell-cycle in-
hibitor p21waf1/cip1 (p21) was increased and paradoxically
required for EGF-directed proliferation of enterocytes
in vitro.78 In this study, a critical region of the p21 promoter
was found to be activated by EGF-receptor stimulation. This
promoter activity required activated extracellular signal-
regulated kinase 1/2 and contained a putative binding site
for the transcription factor Sp1. The requirement for this
cell-cycle regulatory protein was veriﬁed in earlier experi-
ments in which p21-null mice showed no induction of
enterocyte proliferation after the stimulus of SBR.79
In seeking potential mechanisms for how p21 regulates
adaptation, we initially expanded upon the observation that
p21 affects stem cell populations within bone marrow.80 We
therefore sought to determine the effect of p21 deﬁciency
on intestinal stem cells. In these studies, we were unable to
show differences in the expression of several stem cell
markers or numbers of crypt-base columnar cells in p21-
null vs control mice.81 However, we did identify increased
expression of another cell-cycle inhibitor retinoblastoma
protein (Rb) within the crypt cells of the p21-deﬁcient
mice.82 The signiﬁcance of Rb expression was established
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by genetically inactivating a single Rb allele in the p21-null
animals, which restored enterocyte proliferation and adap-
tation responses. In another study, rates of enterocyte
proliferation and villus growth were magniﬁed when Rb
expression was completely disrupted within the intestinal
epithelium of unoperated mice.83
Independent of p21, EGF-receptor stimulation has been
shown to inactivate Rb directly by phosphorylation in
cultured enterocytes.84 One simple explanation for how Rb
deﬁciency results in enterocyte proliferation is the fact that
the activity of this cell-cycle inhibitor is attenuated. Alter-
natively, enhanced IGF-2 expression has been shown to be
associated with Rb deﬁciency in enterocytes.85 In this study,
genetic disruption of IGF-2 expression in intestinal
Rb-deﬁcient mice prevented the mucosal hyperplasia asso-
ciated with Rb deﬁciency. Because acute disruption of in-
testinal Rb expression after intestinal resection results in
ampliﬁed adaptation responses,86 future experiments
focused on illuminating this previously unrecognized role
for Rb as a critical player in the molecular mechanism of
resection-induced enterocyte proliferation and adaptation
appear justiﬁed.
Similar to proliferation, rates of enterocyte apoptosis
also are increased after SBR.87–90 Because rates of enter-
ocyte production must be matched perfectly by rates of
enterocyte loss, these ﬁndings made biological sense. It
appears that the proaptotic Bcl-2 family member Bax is a
major mediator of resection-induced enterocyte apoptosis.
Bax expression is increased in the intestine after SBR,88,91
and coincides with reduced expression of the anti-
apoptotic Bcl-2 family member Bcl-w.91 Indeed, the prolif-
erative crypt compartment is the site for the greatest
changes in Bax and Bcl-w expression.92 When intestinal
resections were performed in Bax-null mice, the expected
increase in enterocyte apoptosis did not occur, despite
normal induction of enterocyte proliferation.93 In the setting
of intestinal resection, apoptotic and adaptive responses are
preserved in both tumor necrosis factor-receptor 1-null and
Fas-null mice.94 These results suggest that the mechanism
for increased enterocyte apoptosis after massive SBR does
not appear to involve the extrinsic, death receptor–mediated
pathway. Furthermore, the apoptosis response to SBR is not
a simple passive response to increased rates of enterocyte
proliferation.
The ultimate utility of focusing on both the rates of
proliferation and apoptosis is that future growth factor and/
or pharmacologic therapy targeted to stimulate proliferation
while at the same time inhibit apoptosis may result in an
even greater expanded mucosal surface area than either
intervention alone. The beneﬁts of this dual therapeutic
approach was suggested by co-administration of EGF (to
inhibit apoptosis and stimulate proliferation) and a phar-
macologic apoptosis (pan-caspase) inhibitor after SBR,
resulting in greater mucosal growth.95 Explicit under-
standing of these mechanisms will be necessary to optimize
this novel therapy. A summary of key signaling events that
have been established to be involved with EGF-directed
enhanced enterocyte proliferation and attenuated rates of
apoptosis is presented in Figure 2.
Angiogenesis
We previously identiﬁed a signiﬁcant induction of capil-
lary growth within adapting intestinal villi.96 It presently is
unclear whether this angiogenic response occurs as a result
of stimulated enterocyte production or whether this angio-
genic response is a primary signal to induce enterocyte pro-
liferation. Photoacoustic microscopy applied to live mice
immediately after intestinal resection showed that both blood
ﬂow and arterial oxygen saturation were reduced and oxygen
extraction was increased within the remnant intestine.97 This
immediate response was associated with increased expres-
sion of hypoxia-inducing factor-1a.98 It therefore is possible
that the immediate response to SBR results in a hypoxic
milieu that may initiate a series of hypoxia-regulated genes
capable of signaling for enterocyte proliferation. This notion
is supported by a study that reported rescued adaptation
responses in the intestine of vascular endothelial growth
factor–deﬁcient mice after SBR.99
One proangiogenic chemokine is CXCL-5, which has been
shown to be increased in the adapting intestine after SBR.96
The expression of endothelial CXCL-5 appears to be modu-
lated by EGF.100 Indeed, genetic disruption of CXCL-5
expression prevents adaptive angiogenesis after SBR.101 In
this study, it was surprising that villus growth occurred
despite the lack of an angiogenic response. In a subsequent
Figure 2. Key signaling events that have been established
to play a role in mechanisms for how EGF ampliﬁes
resection-induced intestinal adaptation. ERK, extracellular
signal-regulated kinase.
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series of experiments, CXCL-5 null mice were found to have
impaired intestinal lipid absorption after SBR.102 It there-
fore is plausible to conclude that the angiogenic response to
intestinal resection is more important for functional, rather
than structural, adaptation.
Gut Microbiome
Small-bowel bacterial overgrowth (SBBO) and catheter-
related bloodstream infections are 2 of the most common
complications in patients with intestinal failure and directly
impact morbidity and mortality.103,104 SBBO generally re-
sults from the development of dilated loops of intestine
with impaired peristalsis. This anatomic alteration sets the
stage for stasis, disruption of the enteric ﬂora, secretory
diarrhea, malabsorption, gut mucosal inﬂammation, D-lactic
acid production, and bacterial translocation into either the
portal circulation or mesenteric lymph nodes. Despite these
well-known events, data supporting the occurrence of
bacterial translocation and microbiologic features of SBBO
in human beings are both limited and indirect. Prior studies
have used cultures of duodenal aspirate, absorption of
various sugar markers as a surrogate for intestinal
permeability, or hydrogen and/or 14C-D-xylose breath
testing. Reliance on culturable organisms alone is restricted
by the fact that less than 50% of bacterial species in the gut
cannot be cultured.
Recent advances in high-throughput sequencing of the
16S ribosomal RNA gene of luminal gut bacteria have
established a signiﬁcant association between the intestinal
microbiome and various intestinal epithelial and metabolic
responses to a wide spectrum of diseases and conditions. By
using 16S sequencing, massive SBR has been shown in
several animal models (mouse, piglet) to be associated with
signiﬁcant alterations in the gut microbiome.105–107
There have been limited pediatric clinical studies
involving the gut microbiome in the context of short-bowel
syndrome. In one report, the gut microbiota in 11 children
with short-bowel syndrome was studied and a reduced
bacterial diversity was found to be associated with an
increased relative abundance of Proteobacteria.108 A con-
founding variable of this study was that the majority of pa-
tients on parenteral nutrition (PN) were receiving antibiotics
at the time of stool sampling. Another 6 patients already had
been weaned from PN. In another study of 23 children with
intestinal failure, there also was reduced bacterial diversity
associated with an increased relative abundance of Proteo-
bacteria in patients who required PN, although there was an
overabundance of Lactobacilli in patients who already had
been weaned from PN.109 In the PN patients, Proteobacteria
was associated with a greater degree of liver injury. These
data offer the possibility that the gut microbiome may be a
major contributor in the pathogenesis of cholestasis and
hepatic injury in patients with intestinal failure.
Mayeur et al110 studied 16 patients with short-gut syn-
drome and showed a marked dysbiosis in fecal microbiota,
with a predominance of the Lactobacillus/Leuconostoc
group, whereas Clostridium and Bacteroides were under-
represented. The presence of fecal lactate (56% of
patients) was used to deﬁne a lactate-accumulator (LA)
group, whereas an absence of fecal lactate (44% of patients)
deﬁned a non–lactate-accumulator group. The LA group had
lower serum HC03- levels and were at risk of D-encepha-
lopathic reactions. Furthermore, all patients in the non-
–lactate-accumulator group and those accumulating
preferentially L isoform in the LA group had never devel-
oped D-acidosis. The D/L fecal lactate ratio therefore may
be a relevant index to predict the risk for D-lactate en-
cephalopathy. There was a recent case report of a child with
D-lactic acidosis and short-bowel syndrome who was
managed successfully by fecal transplantation.111
Through metagenomic and biochemical analysis, the in-
testinal microbiota of genetically obese mice have been
shown to have an increased capacity for energy harvest
from the diet.112 In that study, transfer of stool into the
gastrointestinal tract of germ-free mice resulted in a
signiﬁcant increase in body fat. Stool from obese mice show
a proportional increase in Fermicutes phyla (which includes
the genus Lactobacilli) in their intestinal lumen. It therefore
is plausible to investigate whether the altered intestinal
microbiota in patients with intestinal failure adapts to
provide greater energy harvest for the host.
The paucity of published data regarding direct interro-
gation of the microbiota in the setting of intestinal failure
represents a signiﬁcant gap in our understanding of this
important morbidity. These data will direct a more informed
scientiﬁc rationale for current therapeutic interventions
such as antibiotic administration, prebiotics, probiotics,
surgical reduction in small-bowel caliber, or even future
interventions such as microbiota manipulation via fecal
transplantation.
Conclusions
Adaptation is critical for survival after massive intestinal
loss. In children with intestinal failure, roughly half will
have a complete adaptation response and be weaned
completely from parenteral nutrition.113 Within the other
half of patients, an equal proportion will either die or
require a small-bowel transplant. Current 5-year graft sur-
vival rates after intestinal transplantation are roughly
50%,114 with signiﬁcant patient morbidity associated with
signiﬁcant immunosuppression. Basic research designed to
elucidate speciﬁc mechanisms for resection-induced adap-
tation responses therefore are critical for the future design
of more targeted, innovative therapies to enhance this
important response.
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